Enanta Pharmaceuticals (ENTA) News Today → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free ENTA Stock Alerts $12.47 +0.34 (+2.80%) (As of 04:00 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15, 2024 | americanbankingnews.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Hold" by BrokeragesMay 11, 2024 | americanbankingnews.comHC Wainwright Research Analysts Decrease Earnings Estimates for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)May 10, 2024 | marketbeat.comQ3 2024 EPS Estimates for Enanta Pharmaceuticals, Inc. Decreased by HC Wainwright (NASDAQ:ENTA)Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Investment analysts at HC Wainwright decreased their Q3 2024 earnings per share (EPS) estimates for shares of Enanta Pharmaceuticals in a research report issued on Tuesday, May 7th. HC Wainwright analyst E. Arce now anticipates that the bMay 10, 2024 | americanbankingnews.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to Post Q1 2025 Earnings of ($1.15) Per Share, HC Wainwright ForecastsMay 10, 2024 | americanbankingnews.comEnanta Pharmaceuticals, Inc. to Post Q3 2024 Earnings of ($1.60) Per Share, Leerink Partnrs Forecasts (NASDAQ:ENTA)May 9, 2024 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Forecasted to Post Q1 2025 Earnings of ($1.15) Per ShareEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - HC Wainwright issued their Q1 2025 EPS estimates for Enanta Pharmaceuticals in a research note issued on Tuesday, May 7th. HC Wainwright analyst E. Arce forecasts that the biotechnology company will post earnings per share of ($1.15) forMay 9, 2024 | marketbeat.comEnanta Pharmaceuticals (NASDAQ:ENTA) Stock Rating Upgraded by StockNews.comStockNews.com upgraded Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday.May 8, 2024 | markets.businessinsider.comBuy Rating Affirmed: Enanta Pharmaceuticals’ Clinical and Financial Prospects Bolster Investor ConfidenceMay 8, 2024 | finance.yahoo.comEnanta Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 8, 2024 | markets.businessinsider.comHold Rating on Enanta Pharmaceuticals Amidst Clinical Trials Uncertainty and Financial OutlookMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Enanta Pharmaceuticals Amidst Promising RSV Developments and Clinical Trial ExecutionMay 7, 2024 | marketbeat.comEnanta Pharmaceuticals (NASDAQ:ENTA) Given New $27.00 Price Target at HC WainwrightHC Wainwright dropped their price objective on Enanta Pharmaceuticals from $28.00 to $27.00 and set a "buy" rating on the stock in a research note on Tuesday.May 7, 2024 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call TranscriptMay 7, 2024 | businesswire.comEnanta Pharmaceuticals to Participate at the JMP Securities Life Sciences ConferenceMay 7, 2024 | finance.yahoo.comEnanta Pharmaceuticals Inc (ENTA) (Q2 2024) Earnings Call Transcript Highlights: Navigating ...May 7, 2024 | chron.comEnanta Pharmaceuticals: Fiscal Q2 Earnings SnapshotMay 6, 2024 | finance.yahoo.comEnanta Pharmaceuticals Reports Fiscal Q2 Results: A Closer Look Against Analyst ExpectationsMay 6, 2024 | businesswire.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ETMay 5, 2024 | msn.comEnanta Pharma Q2 2024 Earnings PreviewMay 5, 2024 | markets.businessinsider.comEnanta Pharmaceuticals is about to announce its earnings — here's what to expectMay 3, 2024 | finance.yahoo.comStrong week for Enanta Pharmaceuticals (NASDAQ:ENTA) shareholders doesn't alleviate pain of five-year lossMay 1, 2024 | marketbeat.comFederated Hermes Inc. Acquires New Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Federated Hermes Inc. acquired a new stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 133,189 shares of the biotechnology company's stock,April 30, 2024 | marketbeat.comEnanta Pharmaceuticals (ENTA) Scheduled to Post Earnings on MondayEnanta Pharmaceuticals (NASDAQ:ENTA) will be releasing earnings after the market closes on Monday, May 6, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=591144)April 30, 2024 | businesswire.comEnanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 30, 2024 | businesswire.comEnanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal OfficerApril 29, 2024 | businesswire.comEnanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024April 17, 2024 | finance.yahoo.comEnanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024April 15, 2024 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by Vanguard Group Inc.Vanguard Group Inc. lessened its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 2.7% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,660,520 shares of the bApril 2, 2024 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Sees Significant Growth in Short InterestEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 2,410,000 shares, a growth of 15.3% from the February 29th total of 2,090,000 shares. Currently, 12.3% of the company's shares are sold short. Based on an average daily trading volume, of 263,300 shares, the days-to-cover ratio is currently 9.2 days.March 29, 2024 | marketbeat.comEnanta Pharmaceuticals (NASDAQ:ENTA) Upgraded at StockNews.comStockNews.com upgraded shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Friday.March 19, 2024 | money.usnews.comEnanta Pharmaceuticals IncMarch 19, 2024 | marketbeat.comWalleye Capital LLC Acquires 92,410 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Walleye Capital LLC grew its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 342.8% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 119,364 shares of the biotechnology company's stock after buying an additionaMarch 13, 2024 | seekingalpha.comENTA Enanta Pharmaceuticals, Inc.March 11, 2024 | finance.yahoo.comENTA Oct 2024 20.000 callMarch 11, 2024 | finance.yahoo.comENTA Oct 2024 22.500 callMarch 11, 2024 | finance.yahoo.comENTA Oct 2024 10.000 putMarch 6, 2024 | businesswire.comEnanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma ConferenceMarch 5, 2024 | marketbeat.comShort Interest in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Rises By 20.1%Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) saw a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 2,210,000 shares, a growth of 20.1% from the January 31st total of 1,840,000 shares. Based on an average daily trading volume, of 270,700 shares, the days-to-cover ratio is currently 8.2 days. Currently, 11.2% of the shares of the company are sold short.March 4, 2024 | marketbeat.comTrexquant Investment LP Takes Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Trexquant Investment LP bought a new stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 132,561 shares of the biotechnology company'February 24, 2024 | marketbeat.comJanney Montgomery Scott LLC Buys New Shares in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Janney Montgomery Scott LLC purchased a new stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 62,452 shares of the biotechnology comFebruary 23, 2024 | marketbeat.comAcadian Asset Management LLC Buys 448,201 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Acadian Asset Management LLC boosted its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 445.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 548,782 shares of the biotechnology compaFebruary 16, 2024 | marketbeat.comShort Interest in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Rises By 15.7%Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) was the target of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,840,000 shares, an increase of 15.7% from the January 15th total of 1,590,000 shares. Based on an average daily trading volume, of 283,300 shares, the days-to-cover ratio is currently 6.5 days. Currently, 9.3% of the company's stock are sold short.February 12, 2024 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportFebruary 9, 2024 | markets.businessinsider.comOppenheimer Keeps Their Hold Rating on Enanta Pharmaceuticals (ENTA)February 9, 2024 | markets.businessinsider.comMaintaining Hold on Enanta Pharmaceuticals Amid Near-Term Challenges and Pipeline PotentialFebruary 9, 2024 | marketbeat.comBank of New York Mellon Corp Has $1.21 Million Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Bank of New York Mellon Corp reduced its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 34.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 107,955 shares of the biotechnology coFebruary 8, 2024 | finance.yahoo.comQ1 2024 Enanta Pharmaceuticals Inc Earnings CallFebruary 8, 2024 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2024 Earnings Call TranscriptFebruary 8, 2024 | marketbeat.comLeerink Partnrs Comments on Enanta Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:ENTA)Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Stock analysts at Leerink Partnrs issued their Q2 2024 earnings per share (EPS) estimates for shares of Enanta Pharmaceuticals in a research note issued to investors on Monday, February 5th. Leerink Partnrs analyst R. Ruiz anticipates thaFebruary 7, 2024 | benzinga.comRecap: Enanta Pharma Q1 Earnings Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Boost your retirement with these AI payouts (Ad)BREAKING: New "Formula" Could Lead to Huge AI Payouts When you click here and see what Elon Musk's new invention does… Investors — including multiple billionaires — are now tapping into a unique AI secret to pocket huge, consistent payouts. Starting today, you could siphon a new stream of income from this $3 billion pool of cash. ENTA Media Mentions By Week ENTA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ENTA News Sentiment▼0.010.42▲Average Medical News Sentiment ENTA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ENTA Articles This Week▼12▲ENTA Articles Average Week Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CTMX News Today XERS News Today NKTR News Today XBIT News Today RAPT News Today ELYM News Today INZY News Today XOMA News Today VSTM News Today DSGN News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ENTA) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDoes this make you sick?Allegiance GoldThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
